XSHG600668
Market cap450mUSD
Jan 09, Last price
9.59CNY
1D
-1.34%
1Q
0.10%
Jan 2017
-42.71%
Name
Zhe Jiang Jian Feng Group Co Ltd
Chart & Performance
Profile
Zhejiang Jianfeng Group Co., Ltd. operates in the cement business in China. The company offers ordinary Portland and Portland slag cement products. It also provides pharmaceutical products, including aspartic acid amlodipine tablets for hypertension; heart pills for high blood pressure, dizziness, headache, neck pain, coronary heart disease, angina, nervous headache, and early sudden deafness; paroxetine hydrochloride tablets for various types of anxiety related with depression; vinegar acid chloride Finn zyban products for symptoms caused by osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; spray vial products for severe herpes zoster patients; and sodium hyaluronate eye drops for dry eyes. In addition, the company offers cable products, such as BV line common insulated and household electric wires; HYA series, which are copper core, solid polyolefin insulation block, and communications cables; network lines; RVV series cable mains; and SYWV-75 series physical foaming cables, as well as telecommunication cables. Further, it provides health products comprising boiling Jade Kim tea bags, bomb sugar, Sangge tea, lyophilized Tianma pieces, and broken fungus spore powder, as well as grape seed extract soft, Tianfu, vitamin E nutritional, bone Thai, and goodnight capsules. Additionally, the company offers warehousing and logistics services. It provides products and services through its marketing and sales channels. The company was founded in 1958 and is based in Jinhua, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 2,893,369 -18.73% | 3,560,394 -6.43% | |||||||
Cost of revenue | 2,591,158 | 3,084,435 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 302,211 | 475,959 | |||||||
NOPBT Margin | 10.44% | 13.37% | |||||||
Operating Taxes | 43,680 | 104,590 | |||||||
Tax Rate | 14.45% | 21.97% | |||||||
NOPAT | 258,531 | 371,369 | |||||||
Net income | 93,756 -67.41% | 287,720 -68.86% | |||||||
Dividends | (67,096) | (172,042) | |||||||
Dividend yield | 1.77% | 3.92% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 167,500 | 467,751 | |||||||
Long-term debt | 354,051 | 25,998 | |||||||
Deferred revenue | 47,252 | 42,295 | |||||||
Other long-term liabilities | 59,297 | 98,325 | |||||||
Net debt | (2,094,032) | (2,390,426) | |||||||
Cash flow | |||||||||
Cash from operating activities | 68,981 | 383,330 | |||||||
CAPEX | (237,463) | ||||||||
Cash from investing activities | (222,381) | ||||||||
Cash from financing activities | (33,312) | 43,495 | |||||||
FCF | 165,669 | 230,487 | |||||||
Balance | |||||||||
Cash | 211,279 | 373,161 | |||||||
Long term investments | 2,404,305 | 2,511,014 | |||||||
Excess cash | 2,470,915 | 2,706,156 | |||||||
Stockholders' equity | 4,862,244 | 5,369,832 | |||||||
Invested Capital | 3,623,689 | 3,434,165 | |||||||
ROIC | 7.33% | 11.45% | |||||||
ROCE | 4.96% | 7.75% | |||||||
EV | |||||||||
Common stock shares outstanding | 344,084 | 344,084 | |||||||
Price | 11.03 -13.42% | 12.74 -30.31% | |||||||
Market cap | 3,795,245 -13.42% | 4,383,628 -30.31% | |||||||
EV | 2,060,249 | 2,392,873 | |||||||
EBITDA | 525,686 | 677,306 | |||||||
EV/EBITDA | 3.92 | 3.53 | |||||||
Interest | 19,020 | 16,569 | |||||||
Interest/NOPBT | 6.29% | 3.48% |